Normolose (Captopril)

Captopril, the active ingredient in Normolose, is an ACE inhibitor presented as an oral dosage form for oral use. It is employed to treat hypertension and various forms of heart disease in adult patients. By inhibiting the angiotensin‑converting enzyme, it reduces the formation of angiotensin II, producing vasodilation and lowering aldosterone secretion.

GNH USA supplies Normolose as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company sources the product from EU‑approved manufacturers, ensuring adherence to stringent quality standards and regulatory requirements for global distribution.

Captopril acts on the renin‑angiotensin‑aldosterone system to manage several cardiovascular conditions. - Hypertension: lowers systemic blood pressure and reduces risk of stroke and heart attack. - Congestive heart failure: improves cardiac output and decreases fluid retention. - Diabetic nephropathy: slows progression of kidney damage in patients with diabetes. - Post‑myocardial infarction: reduces mortality and prevents remodeling of the heart.

Captopril may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Cough: dry, persistent cough. - Dizziness or light‑headedness. - Headache. - Fatigue. - Taste disturbances (metallic or altered taste). - Hypotension: especially after first dose.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat. - Severe neutropenia or leukopenia. - Hepatic dysfunction: jaundice or elevated liver enzymes. - Acute renal impairment. - Anaphylactoid reactions. - Hyperkalemia: dangerously high potassium levels.

When prescribing Captopril, clinicians should observe several precautionary measures to ensure patient safety. - Renal function: monitor serum creatinine and potassium levels regularly. - Pregnancy: avoid use unless clearly indicated, as safety data are limited. - Concomitant diuretics: assess risk of excessive blood pressure reduction. - Hyperkalemia: do not combine with potassium‑sparing agents without monitoring. - Drug interactions: review patient medication list for ACE‑inhibitor contraindications. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Captopril interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal impairment and hyperkalemia. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure. - Lithium: Captopril can increase lithium levels; check serum concentrations. - Beta‑blockers: additive blood pressure lowering; observe for excessive bradycardia.